{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:28:03Z","timestamp":1791959283379,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"25","license":[{"start":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T00:00:00Z","timestamp":1587254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T00:00:00Z","timestamp":1587254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009794","name":"Breast Cancer Now","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2020,6,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Combination of CDK4\/6 inhibitors and endocrine therapy improves clinical outcome in advanced oestrogen receptor (ER)-positive breast cancer, however relapse is inevitable. Here, we show in model systems that other than loss of<jats:italic>RB1<\/jats:italic>few gene-copy number (CN) alterations are associated with irreversible-resistance to endocrine therapy and subsequent secondary resistance to palbociclib. Resistance to palbociclib occurred as a result of tumour cell re-wiring leading to increased expression of<jats:italic>EGFR, MAPK, CDK4, CDK2, CDK7, CCNE1<\/jats:italic>and<jats:italic>CCNE2<\/jats:italic>. Resistance altered the ER genome wide-binding pattern, leading to decreased expression of \u2018classical\u2019 oestrogen-regulated genes and was accompanied by reduced sensitivity to fulvestrant and tamoxifen. Persistent CDK4 blockade decreased phosphorylation of tuberous sclerosis complex 2 (TSC2) enhancing EGFR signalling, leading to the re-wiring of ER. Kinome-knockdown confirmed dependency on ERBB-signalling and G2\/M\u2013checkpoint proteins such as WEE1, together with the cell cycle master regulator, CDK7. Noteworthy, sensitivity to CDK7 inhibition was associated with loss of ER and<jats:italic>RB1<\/jats:italic>CN. Overall, we show that resistance to CDK4\/6 inhibitors is dependent on kinase re-wiring and the redeployment of signalling cascades previously associated with endocrine resistance and highlights new therapeutic networks that can be exploited upon relapse after CDK4\/6 inhibition.<\/jats:p>","DOI":"10.1038\/s41388-020-1284-6","type":"journal-article","created":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T13:02:28Z","timestamp":1587301348000},"page":"4781-4797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0880-1588","authenticated-orcid":false,"given":"Sunil","family":"Pancholi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikiana","family":"Simigdala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Nikitorowicz-Buniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ressa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0406-1594","authenticated-orcid":false,"given":"Qiong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Ferreira","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandeep","family":"Bhamra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Thornhill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludivine","family":"Morisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Montaudon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sourd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5093-5945","authenticated-orcid":false,"given":"Maarten","family":"Altelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Marangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4122-744X","authenticated-orcid":false,"given":"Mitch","family":"Dowsett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley-Ann","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,19]]},"reference":[{"key":"1284_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.mce.2013.09.038","volume":"382","author":"N Patani","year":"2014","unstructured":"Patani N, Martin LA. Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer. Mol Cell Endocrinol. 2014;382:683\u201394.","journal-title":"Mol Cell Endocrinol"},{"key":"1284_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1042\/BST0380217","volume":"38","author":"II Witzel","year":"2010","unstructured":"Witzel II, Koh LF, Perkins ND. Regulation of cyclin D1 gene expression. Biochem Soc Trans. 2010;38:217\u201322.","journal-title":"Biochem Soc Trans"},{"key":"1284_CR3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1172\/JCI28803","volume":"117","author":"EE Bosco","year":"2007","unstructured":"Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, et al. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Investig. 2007;117:218\u201328.","journal-title":"J Clin Investig"},{"key":"1284_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0304-3835(94)03676-A","volume":"90","author":"C Dickson","year":"1995","unstructured":"Dickson C, Fantl V, Gillett C, Brookes S, Bartek J, Smith R, et al. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett. 1995;90:43\u201350.","journal-title":"Cancer Lett"},{"key":"1284_CR5","first-page":"1812","volume":"54","author":"C Gillett","year":"1994","unstructured":"Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 1994;54:1812\u20137.","journal-title":"Cancer Res"},{"key":"1284_CR6","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1158\/0008-5472.CAN-05-0746","volume":"65","author":"K Jirstrom","year":"2005","unstructured":"Jirstrom K, Stendahl M, Ryden L, Kronblad A, Bendahl PO, Stal O, et al. Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res. 2005;65:8009\u201316.","journal-title":"Cancer Res"},{"key":"1284_CR7","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1158\/1078-0432.CCR-07-4122","volume":"14","author":"M Rudas","year":"2008","unstructured":"Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, et al. Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Clin Cancer Res. 2008;14:1767\u201374.","journal-title":"Clin Cancer Res"},{"key":"1284_CR8","doi-asserted-by":"publisher","first-page":"R57","DOI":"10.1186\/bcr3161","volume":"14","author":"K Lundgren","year":"2012","unstructured":"Lundgren K, Brown M, Pineda S, Cuzick J, Salter J, Zabaglo L, et al. Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Res. 2012;14:R57.","journal-title":"Breast Cancer Res"},{"key":"1284_CR9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.4161\/cc.9.4.10611","volume":"9","author":"S Paternot","year":"2010","unstructured":"Paternot S, Bockstaele L, Bisteau X, Kooken H, Coulonval K, Roger PP. Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell Cycle. 2010;9:689\u201399.","journal-title":"Cell Cycle"},{"key":"1284_CR10","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.1427.3.11","volume":"3","author":"DW Fry","year":"2004","unstructured":"Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4\/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3:1427\u201338.","journal-title":"Mol Cancer Ther"},{"key":"1284_CR11","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738\u201348.","journal-title":"N Engl J Med"},{"key":"1284_CR12","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925\u201336.","journal-title":"N Engl J Med"},{"key":"1284_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209\u201319.","journal-title":"N Engl J Med"},{"key":"1284_CR14","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1158\/1535-7163.MCT-15-0143","volume":"14","author":"R Ribas","year":"2015","unstructured":"Ribas R, Pancholi S, Guest SK, Marangoni E, Gao Q, Thuleau A. et al. AKT antagonist AZD5363 influences estrogen receptor function in endocrine resistant breast cancer and synergises with fulvestrant (ICI182780) in vivo. Mol Cancer Ther. 2015;14:2035\u201348.","journal-title":"Mol Cancer Ther"},{"key":"1284_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01864-y","volume":"8","author":"LA Martin","year":"2017","unstructured":"Martin LA, Ribas R, Simigdala N, Schuster E, Pancholi S, Tenev T, et al. Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nat Commun. 2017;8:1865.","journal-title":"Nat Commun"},{"key":"1284_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ymeth.2009.03.001","volume":"48","author":"D Schmidt","year":"2009","unstructured":"Schmidt D, Wilson MD, Spyrou C, Brown GD, Hadfield J, Odom DT. ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. Methods. 2009;48:240\u20138.","journal-title":"Methods"},{"key":"1284_CR17","unstructured":"Stark R, Brown GD. DiffBind: differential binding analysis of ChIP-Seq peak data, 2011."},{"key":"1284_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13058-016-0713-5","volume":"18","author":"N Simigdala","year":"2016","unstructured":"Simigdala N, Gao Q, Pancholi S, Roberg-Larsen H, Zvelebil M, Ribas R, et al. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer. Breast Cancer Res. 2016;18:58.","journal-title":"Breast Cancer Res"},{"key":"1284_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nprot.2013.010","volume":"8","author":"H Zhou","year":"2013","unstructured":"Zhou H, Ye M, Dong J, Corradini E, Cristobal A, Heck AJ, et al. Robust phosphoproteome enrichment using monodisperse microsphere-based immobilized titanium (IV) ion affinity chromatography. Nat Protoc. 2013;8:461\u201380.","journal-title":"Nat Protoc"},{"key":"1284_CR20","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1021\/acs.jproteome.8b00576","volume":"18","author":"A Ressa","year":"2018","unstructured":"Ressa A, Fitzpatrick M, Van den Toorn H, Heck AJR, Altelaar M. PaDuA: a Python library for high-throughput (phospho)proteomic data analysis. J. Proteome Res.2018;18:576\u201384.","journal-title":"J. Proteome Res."},{"key":"1284_CR21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.cels.2016.11.005","volume":"3","author":"JD Rudolph","year":"2016","unstructured":"Rudolph JD, de Graauw M, van de Water B, Geiger T, Sharan R. Elucidation of signaling pathways from large-scale phosphoproteomic data using protein interaction networks. Cell Syst. 2016;3:585\u201393. e583.","journal-title":"Cell Syst"},{"key":"1284_CR22","doi-asserted-by":"publisher","first-page":"4332","DOI":"10.1021\/acs.jproteome.5b00529","volume":"14","author":"LM Raaijmakers","year":"2015","unstructured":"Raaijmakers LM, Giansanti P, Possik PA, Mueller J, Peeper DS, Heck AJ, et al. PhosphoPath: visualization of phosphosite-centric dynamics in temporal molecular networks. J Proteome Res. 2015;14:4332\u201341.","journal-title":"J Proteome Res"},{"key":"1284_CR23","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1158\/2159-8290.CD-11-0107","volume":"1","author":"R Brough","year":"2011","unstructured":"Brough R, Frankum JR, Sims D, Mackay A, Mendes-Pereira AM, Bajrami I, et al. Functional viability profiles of breast cancer. Cancer Discov. 2011;1:260\u201373.","journal-title":"Cancer Discov"},{"key":"1284_CR24","first-page":"297","volume":"9","author":"EJ Smith","year":"1998","unstructured":"Smith EJ, Leone G, Nevins JR. Distinct mechanisms control the accumulation of the Rb-related p107 and p130 proteins during cell growth. Cell Growth Differ. 1998;9:297\u2013303.","journal-title":"Cell Growth Differ"},{"key":"1284_CR25","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","volume":"76","author":"MT Herrera-Abreu","year":"2016","unstructured":"Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, et al. Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 2016;76:2301\u201313.","journal-title":"Cancer Res"},{"key":"1284_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8166-7-8","volume":"7","author":"M Rondon-Lagos","year":"2014","unstructured":"Rondon-Lagos M, Verdun Di Cantogno L, Marchio C, Rangel N, Payan-Gomez C, Gugliotta P, et al. Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis. Mol Cytogenet. 2014;7:8.","journal-title":"Mol Cytogenet"},{"key":"1284_CR27","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1101\/gad.1944810","volume":"24","author":"M Lupien","year":"2010","unstructured":"Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T, et al. Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev. 2010;24:2219\u201327.","journal-title":"Genes Dev"},{"key":"1284_CR28","doi-asserted-by":"publisher","first-page":"11354","DOI":"10.1158\/0008-5472.CAN-05-2236","volume":"65","author":"SJ Zacharek","year":"2005","unstructured":"Zacharek SJ, Xiong Y, Shumway SD. Negative regulation of TSC1-TSC2 by mammalian D-type cyclins. Cancer Res. 2005;65:11354\u201360.","journal-title":"Cancer Res"},{"key":"1284_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","volume":"19","author":"S Chandarlapaty","year":"2011","unstructured":"Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell. 2011;19:58\u201371.","journal-title":"Cancer Cell"},{"key":"1284_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ccell.2016.02.006","volume":"29","author":"S Goel","year":"2016","unstructured":"Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4\/6 inhibitors. Cancer Cell. 2016;29:255\u201369.","journal-title":"Cancer Cell"},{"key":"1284_CR31","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"1284_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14:130\u201346.","journal-title":"Nat Rev Drug Discov"},{"key":"1284_CR33","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nrc3090","volume":"11","author":"EA Musgrove","year":"2011","unstructured":"Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer. 2011;11:558\u201372.","journal-title":"Nat Rev Cancer"},{"key":"1284_CR34","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638\u201346.","journal-title":"J Clin Oncol"},{"key":"1284_CR35","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-16-3206","volume":"23","author":"CX Ma","year":"2017","unstructured":"Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, et al. NeoPalAna: Neoadjuvant Palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer. Clin Cancer Res. 2017;23:4055\u201365.","journal-title":"Clin Cancer Res."},{"key":"1284_CR36","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/2159-8290.CD-11-0101","volume":"1","author":"TW Miller","year":"2011","unstructured":"Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, et al. ERalpha-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 2011;1:338\u201351.","journal-title":"Cancer Discov"},{"key":"1284_CR37","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1158\/1078-0432.CCR-13-2602","volume":"20","author":"Q Gao","year":"2014","unstructured":"Gao Q, Patani N, Dunbier AK, Ghazoui Z, Zvelebil M, Martin LA, et al. Effect of aromatase inhibition on functional gene modules in estrogen receptor-positive breast cancer and their relationship with antiproliferative response. Clin Cancer Res. 2014;20:2485\u201394.","journal-title":"Clin Cancer Res"},{"key":"1284_CR38","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","volume":"8","author":"B O\u2019Leary","year":"2018","unstructured":"O\u2019Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8:1390\u2013403.","journal-title":"Cancer Discov"},{"key":"1284_CR39","doi-asserted-by":"publisher","first-page":"7487","DOI":"10.1128\/MCB.00799-08","volume":"28","author":"P Bhat-Nakshatri","year":"2008","unstructured":"Bhat-Nakshatri P, Wang G, Appaiah H, Luktuke N, Carroll JS, Geistlinger TR, et al. AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer. Mol Cell Biol. 2008;28:7487\u2013503.","journal-title":"Mol Cell Biol"},{"key":"1284_CR40","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1038\/sj.onc.1205211","volume":"21","author":"E Grinstein","year":"2002","unstructured":"Grinstein E, Jundt F, Weinert I, Wernet P, Royer HD. Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells. Oncogene. 2002;21:1485\u201392.","journal-title":"Oncogene"},{"key":"1284_CR41","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1038\/onc.2016.379","volume":"36","author":"C Yang","year":"2016","unstructured":"Yang C, Li Z, Bhatt T, Dickler M, Giri D, Scaltriti M. et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence. Oncogene. 2016;36:2255\u201364.","journal-title":"Oncogene"},{"key":"1284_CR42","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1158\/0008-5472.CAN-12-4265","volume":"73","author":"A Morandi","year":"2013","unstructured":"Morandi A, Martin LA, Gao Q, Pancholi S, Mackay A, Robertson D, et al. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors. Cancer Res. 2013;73:3783\u201395.","journal-title":"Cancer Res"},{"key":"1284_CR43","doi-asserted-by":"publisher","first-page":"27155","DOI":"10.18632\/oncotarget.15676","volume":"8","author":"K Bhinge","year":"2017","unstructured":"Bhinge K, Yang L, Terra S, Nasir A, Muppa P, Aubry MC, et al. EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression. Oncotarget. 2017;8:27155\u201365.","journal-title":"Oncotarget"},{"key":"1284_CR44","doi-asserted-by":"publisher","first-page":"e02872","DOI":"10.7554\/eLife.02872","volume":"3","author":"AM Narasimha","year":"2014","unstructured":"Narasimha AM, Kaulich M, Shapiro GS, Choi YJ, Sicinski P, Dowdy SF. Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. eLife. 2014;3:e02872","journal-title":"eLife"},{"key":"1284_CR45","first-page":"419","volume":"1","author":"R Halaban","year":"1998","unstructured":"Halaban R, Miglarese MR, Smicun Y, Puig S. Melanomas, from the cell cycle point of view (Review). Int J Mol Med. 1998;1:419\u201325.","journal-title":"Int J Mol Med"},{"key":"1284_CR46","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1128\/MCB.00057-14","volume":"34","author":"AS Shaw","year":"2014","unstructured":"Shaw AS, Kornev AP, Hu J, Ahuja LG, Taylor SS. Kinases and pseudokinases: lessons from RAF. Mol Cell Biol. 2014;34:1538\u201346.","journal-title":"Mol Cell Biol"},{"key":"1284_CR47","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/sj.onc.1203305","volume":"19","author":"G De Falco","year":"2000","unstructured":"De Falco G, Bagella L, Claudio PP, De Luca A, Fu Y, Calabretta B, et al. Physical interaction between CDK9 and B-Myb results in suppression of B-Myb gene autoregulation. Oncogene. 2000;19:373\u20139.","journal-title":"Oncogene"},{"key":"1284_CR48","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1242\/jcs.02718","volume":"118","author":"RP Fisher","year":"2005","unstructured":"Fisher RP. Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci. 2005;118:5171\u201380.","journal-title":"J Cell Sci"},{"key":"1284_CR49","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1158\/0008-5472.CAN-16-2546","volume":"77","author":"B Li","year":"2017","unstructured":"Li B, Ni Chonghaile T, Fan Y, Madden SF, Klinger R, O\u2019Connor AE, et al. Therapeutic rationale to target highly expressed CDK7 conferring poor outcomes in triple-negative breast cancer. Cancer Res. 2017;77:3834\u201345.","journal-title":"Cancer Res"},{"key":"1284_CR50","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nature13393","volume":"511","author":"N Kwiatkowski","year":"2014","unstructured":"Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014;511:616\u201320.","journal-title":"Nature"},{"key":"1284_CR51","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1535-7163.MCT-16-0847","volume":"17","author":"H Patel","year":"2018","unstructured":"Patel H, Periyasamy M, Sava GP, Bondke A, Slafer BW, Kroll SHB, et al. ICEC0942, an orally bioavailable selective inhibitor of cdk7 for cancer treatment. Mol Cancer Ther. 2018;17:1156\u201366.","journal-title":"Mol Cancer Ther"},{"key":"1284_CR52","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","volume":"37","author":"CJ Matheson","year":"2016","unstructured":"Matheson CJ, Backos DS, Reigan P. Targeting WEE1 kinase in cancer. Trends Pharmacol Sci. 2016;37:872\u201381.","journal-title":"Trends Pharmacol Sci"},{"key":"1284_CR53","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1158\/1535-7163.MCT-17-0537","volume":"17","author":"C Michaloglou","year":"2018","unstructured":"Michaloglou C, Crafter C, Siersbaek R, Delpuech O, Curwen JO, Carnevalli LS, et al. Combined inhibition of mTOR and CDK4\/6 is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor-positive breast cancer. Mol Cancer Ther. 2018;17:908\u201320.","journal-title":"Mol Cancer Ther"},{"key":"1284_CR54","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1158\/1078-0432.CCR-18-3274","volume":"25","author":"NM Kettner","year":"2019","unstructured":"Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, et al. Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer. Clin Cancer Res. 2019;25:3996\u20134013.","journal-title":"Clin Cancer Res"},{"key":"1284_CR55","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-16-2653","volume":"77","author":"VM Jansen","year":"2017","unstructured":"Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, et al. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4\/6 inhibition in ER-positive breast cancer. Cancer Res. 2017;77:2488\u201399.","journal-title":"Cancer Res"},{"key":"1284_CR56","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1158\/1078-0432.CCR-18-0410","volume":"24","author":"R de Leeuw","year":"2018","unstructured":"de Leeuw R, McNair C, Schiewer MJ, Neupane NP, Brand LJ, Augello MA, et al. MAPK reliance via acquired CDK4\/6 inhibitor resistance in cancer. Clin Cancer Res. 2018;24:4201\u201314.","journal-title":"Clin Cancer Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-1284-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-1284-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-020-1284-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:20:52Z","timestamp":1684617652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-020-1284-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,19]]},"references-count":56,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2020,6,18]]}},"alternative-id":["1284"],"URL":"https:\/\/doi.org\/10.1038\/s41388-020-1284-6","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,19]]},"assertion":[{"value":"24 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SRJ, MD and LAM receive academic funding from Pfizer, Puma Biotechnology Inc. and AstraZeneca. MD receives honoraria from Myriad Genetics and speaker\u2019s bureau of Roche, is a consultant and advisory board member of Radius, GTx and Orion Pharma and has received remuneration from the ICR rewards to Inventors Schemes. SRJ is a consultant\/independent contractor for AstraZeneca, Novartis, Pfizer, OBI, Eli Lilly and Company and is on the speaker\u2019s bureau for OBI and Puma. No potential conflict of interests was disclosed by the other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}